146 related articles for article (PubMed ID: 12130532)
1. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene.
Magnusson MK; Meade KE; Nakamura R; Barrett J; Dunbar CE
Blood; 2002 Aug; 100(3):1088-91. PubMed ID: 12130532
[TBL] [Abstract][Full Text] [Related]
2. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia.
Magnusson MK; Meade KE; Brown KE; Arthur DC; Krueger LA; Barrett AJ; Dunbar CE
Blood; 2001 Oct; 98(8):2518-25. PubMed ID: 11588050
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): case report.
Choi IK; Kim BS; Lee KA; Ryu S; Seo HY; Sul H; Choi JG; Sung HJ; Park KH; Yoon SY; Oh SC; Seo JH; Choi CW; Shin SW; Yoon SY; Cho Y; Kim YK; Kim YH; Kim JS
Am J Hematol; 2004 Dec; 77(4):366-9. PubMed ID: 15551277
[TBL] [Abstract][Full Text] [Related]
4. Trisomy 8 in PDGFRB-negative cells in a patient with imatinib-sensitive chronic myelomonocytic leukemia and t(5;16)(q33;p13), PDGFRB-NDE1 fusion.
Cavazzini F; Bardi A; Ciccone M; Rigolin GM; Gorello P; La Starza R; Mecucci C; Cuneo A
Cancer Genet Cytogenet; 2009 Oct; 194(1):67-9. PubMed ID: 19737658
[No Abstract] [Full Text] [Related]
5. Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia.
Gunby RH; Cazzaniga G; Tassi E; Le Coutre P; Pogliani E; Specchia G; Biondi A; Gambacorti-Passerini C
Haematologica; 2003 Apr; 88(4):408-15. PubMed ID: 12681968
[TBL] [Abstract][Full Text] [Related]
6. TV6 and PDGFRB: a license to fuse.
Lierman E; Cools J
Haematologica; 2007 Feb; 92(2):145-7. PubMed ID: 17296561
[No Abstract] [Full Text] [Related]
7. Detection of trisomy 8 in donor-derived Ph- cells in a patient with Ph+ chronic myeloid leukemia successfully treated with Imatinib (STI571) in relapse after allogeneic transplantation.
Agis H; Mannhalter C; Sperr WR; Keil F; Kalhs P; Pirc-Danoewinata H; Krauth MT; Haas OA; Geissler K; Lechner K; Valent P
Leuk Lymphoma; 2004 Jul; 45(7):1453-8. PubMed ID: 15359647
[TBL] [Abstract][Full Text] [Related]
8. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2).
Ross TS; Bernard OA; Berger R; Gilliland DG
Blood; 1998 Jun; 91(12):4419-26. PubMed ID: 9616134
[TBL] [Abstract][Full Text] [Related]
9. A Novel PCM1-PDGFRB Fusion in a Patient with a Chronic Myeloproliferative Neoplasm and an ins(8;5).
Ghazzawi M; Mehra V; Knut M; Brown L; Tapper W; Chase A; de Lavallade H; Cross NCP
Acta Haematol; 2017; 138(4):198-200. PubMed ID: 29169164
[No Abstract] [Full Text] [Related]
10. Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptor involvement: a new case report.
Pitini V; Arrigo C; Teti D; Barresi G; Righi M; Alo G
Haematologica; 2003 May; 88(5):ECR18. PubMed ID: 12745287
[TBL] [Abstract][Full Text] [Related]
11. Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder.
Oravecz-Wilson KI; Philips ST; Yilmaz OH; Ames HM; Li L; Crawford BD; Gauvin AM; Lucas PC; Sitwala K; Downing JR; Morrison SJ; Ross TS
Cancer Cell; 2009 Aug; 16(2):137-48. PubMed ID: 19647224
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature.
Müller AM; Martens UM; Hofmann SC; Bruckner-Tuderman L; Mertelsmann R; Lübbert M
Ann Hematol; 2006 Jan; 85(1):1-16. PubMed ID: 16136348
[TBL] [Abstract][Full Text] [Related]
13. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
Cancer; 2002 May; 94(10):2653-62. PubMed ID: 12173333
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro.
Dziba JM; Ain KB
J Clin Endocrinol Metab; 2004 May; 89(5):2127-35. PubMed ID: 15126530
[TBL] [Abstract][Full Text] [Related]
15. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.
Cheah CY; Burbury K; Apperley JF; Huguet F; Pitini V; Gardembas M; Ross DM; Forrest D; Genet P; Rousselot P; Patton N; Smith G; Dunbar CE; Ito S; Aguiar RC; Odenike O; Gimelfarb A; Cross NC; Seymour JF
Blood; 2014 Jun; 123(23):3574-7. PubMed ID: 24687085
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.
Metzgeroth G; Walz C; Erben P; Popp H; Schmitt-Graeff A; Haferlach C; Fabarius A; Schnittger S; Grimwade D; Cross NC; Hehlmann R; Hochhaus A; Reiter A
Br J Haematol; 2008 Dec; 143(5):707-15. PubMed ID: 18950453
[TBL] [Abstract][Full Text] [Related]
17. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
[TBL] [Abstract][Full Text] [Related]
18. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.
David M; Cross NC; Burgstaller S; Chase A; Curtis C; Dang R; Gardembas M; Goldman JM; Grand F; Hughes G; Huguet F; Lavender L; McArthur GA; Mahon FX; Massimini G; Melo J; Rousselot P; Russell-Jones RJ; Seymour JF; Smith G; Stark A; Waghorn K; Nikolova Z; Apperley JF
Blood; 2007 Jan; 109(1):61-4. PubMed ID: 16960151
[TBL] [Abstract][Full Text] [Related]
19. Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma.
Kim R; Emi M; Arihiro K; Tanabe K; Uchida Y; Toge T
Cancer; 2005 May; 103(9):1800-9. PubMed ID: 15786421
[TBL] [Abstract][Full Text] [Related]
20. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.
Topaly J; Zeller WJ; Fruehauf S
Leukemia; 2001 Mar; 15(3):342-7. PubMed ID: 11237055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]